Literature DB >> 16774683

Challenging the concept of microinvasive carcinoma of the vulva: report of a case with regional lymph node recurrence and review of the literature.

Jutta Sidor1, Raihana Diallo-Danebrock, Elke Eltze, Ralph J Lellé.   

Abstract

BACKGROUND: It is widely accepted that vulvar carcinoma with a depth of invasion of less than one millimeter is sufficiently treated by vulvectomy or wide local excision without inguinal lymphadenectomy. CASE
PRESENTATION: However, a patient with inguinal lymph node recurrence 21 months after radical vulvectomy for stage IA squamous cell carcinoma was observed.
CONCLUSION: According to a review of the literature, there are five additional cases of metastasizing vulvar cancer with a depth of invasion of less than one millimeter. Therefore, the definition of microinvasive carcinoma of the vulva based on depth of invasion alone may not be as reliable as previously thought and does not rule out inguinal lymph node involvement or recurrence. Consequently, the necessity of inguinal node dissection for microinvasive carcinoma needs to be discussed on an individual basis taking into account the age of the patient as well as the potential morbidity of extended surgery.

Entities:  

Mesh:

Year:  2006        PMID: 16774683      PMCID: PMC1513243          DOI: 10.1186/1471-2407-6-157

Source DB:  PubMed          Journal:  BMC Cancer        ISSN: 1471-2407            Impact factor:   4.430


  17 in total

1.  Lymphatic mapping of sentinel nodes in early vulvar cancer.

Authors:  G Sliutz; A Reinthaller; T Lantzsch; T Mende; H Sinzinger; C Kainz; H Koelbl
Journal:  Gynecol Oncol       Date:  2002-03       Impact factor: 5.482

2.  A stage Ia vulvar carcinoma with an inguinal lymph node recurrence after local excision. A case report and literature review.

Authors:  J. Van Der Velden; C.D. Kooyman; A.C.M. Van Lindert; A.P.M. Heintz
Journal:  Int J Gynecol Cancer       Date:  1992-05       Impact factor: 3.437

3.  The surgery of 'inguino-femoral' lymph nodes: is it adequate or excessive?

Authors:  C N Hudson; H Shulver; D C Lowe
Journal:  Int J Gynecol Cancer       Date:  2004 Sep-Oct       Impact factor: 3.437

4.  Anatomosurgical implications derived from an embryological study of the Scarpa's triangle with particular reference to groin lymphadenectomy.

Authors:  L Micheletti; A C Levi; F Bogliatto
Journal:  Gynecol Oncol       Date:  1998-09       Impact factor: 5.482

5.  Squamous cell carcinoma of the vulva stage IA: long-term results.

Authors:  J F Magrina; J Gonzalez-Bosquet; A L Weaver; T A Gaffey; K O Leslie; M J Webb; K C Podratz
Journal:  Gynecol Oncol       Date:  2000-01       Impact factor: 5.482

6.  Regional lymph node recurrence following local excision for microinvasive vulvar carcinoma.

Authors:  F Atamdede; D Hoogerland
Journal:  Gynecol Oncol       Date:  1989-07       Impact factor: 5.482

7.  Outcomes for patients with T1 squamous cell cancer of the vulva undergoing sentinel node biopsy.

Authors:  Keith Y Terada; David M Shimizu; Caroline S Jiang; Jan H Wong
Journal:  Gynecol Oncol       Date:  2006-01-09       Impact factor: 5.482

Review 8.  Changes in the management of vulval cancer.

Authors:  Kalyan K Dhar; Robert P Woolas
Journal:  Best Pract Res Clin Obstet Gynaecol       Date:  2003-08       Impact factor: 5.237

9.  Microinvasive carcinoma of the vulva.

Authors:  E J Wilkinson; M J Rico; K K Pierson
Journal:  Int J Gynecol Pathol       Date:  1982       Impact factor: 2.762

10.  Prognostic significance of lymph node variables and human papillomavirus DNA in invasive vulvar carcinoma.

Authors:  Alvaro P Pinto; Nicolas F Schlecht; Javier Pintos; Jane Kaiano; Eduardo L Franco; Christopher P Crum; Luisa L Villa
Journal:  Gynecol Oncol       Date:  2004-03       Impact factor: 5.482

View more
  1 in total

1.  Management of patients with vulvar cancer: a perspective review according to tumour stage.

Authors:  Linn Woelber; Fabian Trillsch; Lilli Kock; Donata Grimm; Cordula Petersen; Matthias Choschzick; Fritz Jaenicke; Sven Mahner
Journal:  Ther Adv Med Oncol       Date:  2013-05       Impact factor: 8.168

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.